Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on October 15, 2024, to update its previous offering terms. The supplement amends the prior prospectus, which included filings from January 13, 2023, and subsequent dates throughout 2023 and 2024. The amendment allows Cingulate to offer and sell additional shares of common stock up to the value of $8,340,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This is in line with the limitations set by General Instruction I.B.6, considering the current public float of Cingulate's common stock. As of October 15, 2024, the public float was valued at $53,724,530.00, based on the closing price of $17.69 per share on August 16, 2024. The company has previously sold securities worth $9,567,642.09 in the 12 months leading up to the date of the prospectus. The last reported sale price of Cingulate's common stock was $4.84 per share on October 11, 2024.

Cingulate, a company listed on the Nasdaq Capital Market under the symbol 'CING', has filed a prospectus supplement on October 15, 2024, to update its previous offering terms. The supplement amends the prior prospectus, which included filings from January 13, 2023, and subsequent dates throughout 2023 and 2024. The amendment allows Cingulate to offer and sell additional shares of common stock up to the value of $8,340,000 through H.C. Wainwright & Co., LLC, acting as the sales agent. This is in line with the limitations set by General Instruction I.B.6, considering the current public float of Cingulate's common stock. As of October 15, 2024, the public float was valued at $53,724,530.00, based on the closing price of $17.69 per share on August 16, 2024. The company has previously sold securities worth $9,567,642.09 in the 12 months leading up to the date of the prospectus. The last reported sale price of Cingulate's common stock was $4.84 per share on October 11, 2024.